Login to Your Account



Clinic Roundup


Tuesday, September 20, 2011
Spinifex Pharmaceuticals Pty. Ltd., of Victoria, Australia, said the first patients have been treated in its Phase II trial of EMA401, an angiotensin II Type II receptor antagonist, in postherpetic neuralgia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription